Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Celldex Therapeutics (NASDAQ:CLDX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
This table compares Cardio Diagnostics and Celldex Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
77.3% of Cardio Diagnostics shares are owned by institutional investors. 2.7% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cardio Diagnostics presently has a consensus price target of $8.00, suggesting a potential upside of 627.27%. Celldex Therapeutics has a consensus price target of $66.67, suggesting a potential upside of 48.02%. Given Cardio Diagnostics’ higher possible upside, equities research analysts clearly believe Cardio Diagnostics is more favorable than Celldex Therapeutics.
Valuation and Earnings
This table compares Cardio Diagnostics and Celldex Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Celldex Therapeutics||$4.65 million||456.21||-$70.51 million||($2.26)||-19.93|
Cardio Diagnostics has higher earnings, but lower revenue than Celldex Therapeutics.
Cardio Diagnostics beats Celldex Therapeutics on 6 of the 9 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.